28317028|t|Mycobacterial Caseinolytic Protease Gene Regulator ClgR Is a Substrate of Caseinolytic Protease
28317028|a|The mycobacterial caseinolytic protease ClpP1P2 is a degradative protease that recently gained interest as a genetically and pharmacologically validated drug target for tuberculosis. The first whole-cell active ClpP1P2 inhibitor, the human proteasome inhibitor bortezomib, is currently undergoing lead optimization to introduce selectivity for the bacterial target. How inhibition of ClpP1P2 translates into whole-cell antimicrobial activity is little understood. Previous work has shown that the caseinolytic protease gene regulator ClgR is an activator of the clpP1P2 genes and also suggested that this transcription factor may be a substrate of the protease. Here, we employ promoter activity reporters and direct mRNA level measurements showing that bortezomib treatment of Mycobacterium bovis BCG increased transcription of clpP1P2 and other ClgR - dependent promoters, suggesting that inhibition of ClpP1P2 increases cellular ClgR levels. Then, we carried out red fluorescent protein - ClgR fusion analyses to show that ClgR is indeed a substrate of ClpP1P2 and to identify ClgR's C-terminal nonapeptide APVVSLAVA as the signal sufficient for recognition and efficient protein degradation by ClpP1P2. Interestingly, accumulation of ClgR appears to be toxic for bacilli, suggesting a mechanism for how pharmacological inhibition of ClpP1P2 protease activity by bortezomib translates into whole-cell antibacterial activity. IMPORTANCE With 9 million new cases and more than 1 million deaths per year, tuberculosis, caused by Mycobacterium tuberculosis, is the biggest infectious disease killer globally. New drugs for the treatment of the drug-resistant forms of the disease are needed. Recently, a new target -lead couple, the mycobacterial protease ClpP1P2 and the human anticancer drug bortezomib, was identified. However, we know little about how expression of this protease is regulated, which proteins in the bacterium it degrades, how the protease recognizes its target proteins, and how the inhibition of ClpP1P2 exerts whole-cell antimicrobial activity. Here, we show that the ClpP1P2 protease regulates its own expression, and we identified a new substrate and a new substrate recognition sequence and a mechanism for how ClpP1P2 inhibition causes bacterial growth inhibition.
28317028	0	13	Mycobacterial	T007	C0026912
28317028	14	50	Caseinolytic Protease Gene Regulator	T116,T123	C1336776
28317028	51	55	ClgR	T116,T123	C1336776
28317028	61	70	Substrate	T167	C3891814
28317028	74	95	Caseinolytic Protease	T116,T126	C0052605
28317028	100	113	mycobacterial	T007	C0026912
28317028	114	135	caseinolytic protease	T116,T126	C0052605
28317028	136	143	ClpP1P2	T116,T126	C0052605
28317028	149	169	degradative protease	T116,T126	C0030940
28317028	205	216	genetically	T169	C0314603
28317028	221	238	pharmacologically	T169	C0205464
28317028	249	253	drug	T121	C0013227
28317028	254	260	target	T169	C1521840
28317028	265	277	tuberculosis	T047	C0041296
28317028	307	314	ClpP1P2	T116,T126	C0052605
28317028	315	324	inhibitor	T121	C0014432
28317028	330	335	human	T016	C0086418
28317028	336	356	proteasome inhibitor	T121	C1443643
28317028	357	367	bortezomib	T109,T121	C1176309
28317028	398	410	optimization	T052	C2698650
28317028	444	453	bacterial	T007	C0004611
28317028	454	460	target	T169	C1521840
28317028	466	476	inhibition	T039	C1524081
28317028	480	487	ClpP1P2	T116,T126	C0052605
28317028	515	537	antimicrobial activity	T044	C1149574
28317028	593	629	caseinolytic protease gene regulator	T116,T123	C1336776
28317028	630	634	ClgR	T116,T123	C1336776
28317028	641	650	activator	T045	C0599555
28317028	658	671	clpP1P2 genes	T028	C1335528
28317028	701	721	transcription factor	T116,T123	C0040648
28317028	731	740	substrate	T167	C3891814
28317028	748	756	protease	T116,T126	C0030940
28317028	774	782	promoter	T114,T123	C0086860
28317028	783	791	activity	T052	C0441655
28317028	806	836	direct mRNA level measurements	T034	C1254360
28317028	850	860	bortezomib	T109,T121	C1176309
28317028	861	870	treatment	T169	C1522326
28317028	874	897	Mycobacterium bovis BCG	T007	C0085957
28317028	898	907	increased	T081	C0205217
28317028	908	921	transcription	T045	C0040649
28317028	925	932	clpP1P2	T028	C1335528
28317028	943	947	ClgR	T116,T123	C1336776
28317028	950	959	dependent	T169	C3244310
28317028	960	969	promoters	T114,T123	C0086860
28317028	987	997	inhibition	T039	C1524081
28317028	1001	1008	ClpP1P2	T116,T126	C0052605
28317028	1009	1018	increases	T169	C0442805
28317028	1019	1027	cellular	T025	C0007634
28317028	1028	1032	ClgR	T116,T123	C1336776
28317028	1033	1039	levels	T080	C0441889
28317028	1062	1085	red fluorescent protein	T116	C0960938
28317028	1088	1092	ClgR	T116,T123	C1336776
28317028	1093	1099	fusion	T061	C1293131
28317028	1100	1108	analyses	T062	C0936012
28317028	1122	1126	ClgR	T116,T123	C1336776
28317028	1139	1148	substrate	T167	C3891814
28317028	1152	1159	ClpP1P2	T116,T126	C0052605
28317028	1167	1175	identify	T080	C0205396
28317028	1176	1182	ClgR's	T116,T123	C1336776
28317028	1183	1215	C-terminal nonapeptide APVVSLAVA	T116	C0030956
28317028	1223	1229	signal	T067	C1710082
28317028	1245	1256	recognition	T044	C0599844
28317028	1261	1270	efficient	T080	C0442799
28317028	1271	1290	protein degradation	T044	C0597304
28317028	1294	1301	ClpP1P2	T116,T126	C0052605
28317028	1318	1330	accumulation	T033	C4055506
28317028	1334	1338	ClgR	T116,T123	C1336776
28317028	1353	1358	toxic	T080	C1407029
28317028	1363	1370	bacilli	T007	C0004587
28317028	1385	1394	mechanism	T044	C3537153
28317028	1403	1418	pharmacological	T169	C0205464
28317028	1419	1429	inhibition	T039	C1524081
28317028	1433	1449	ClpP1P2 protease	T116,T126	C0052605
28317028	1450	1458	activity	T044	C0243102
28317028	1462	1472	bortezomib	T109,T121	C1176309
28317028	1500	1522	antibacterial activity	T044	C1149575
28317028	1554	1559	cases	T077	C1706256
28317028	1584	1590	deaths	T033	C1306577
28317028	1591	1599	per year	T079	C0439508
28317028	1601	1613	tuberculosis	T047	C0041296
28317028	1625	1651	Mycobacterium tuberculosis	T007	C0026926
28317028	1668	1686	infectious disease	T047	C0009450
28317028	1708	1713	drugs	T121	C0013227
28317028	1722	1731	treatment	T169	C1522326
28317028	1739	1759	drug-resistant forms	T080	C0205556
28317028	1767	1774	disease	T047	C0012634
28317028	1803	1809	target	T169	C1521840
28317028	1828	1841	mycobacterial	T007	C0026912
28317028	1842	1850	protease	T116,T126	C0030940
28317028	1851	1858	ClpP1P2	T116,T126	C0052605
28317028	1867	1872	human	T016	C0086418
28317028	1873	1888	anticancer drug	T109,T121	C0003392
28317028	1889	1899	bortezomib	T109,T121	C1176309
28317028	1905	1915	identified	T080	C0205396
28317028	1951	1961	expression	T045	C1171362
28317028	1970	1978	protease	T116,T126	C0052605
28317028	1982	1991	regulated	T045	C2755857
28317028	1999	2007	proteins	T116,T123	C0033684
28317028	2015	2024	bacterium	T007	C0004611
28317028	2028	2036	degrades	T044	C0597304
28317028	2046	2054	protease	T116,T126	C0030940
28317028	2070	2076	target	T169	C1521840
28317028	2077	2085	proteins	T116,T123	C0033684
28317028	2099	2109	inhibition	T039	C1524081
28317028	2113	2120	ClpP1P2	T116,T126	C0052605
28317028	2139	2161	antimicrobial activity	T044	C1149574
28317028	2186	2202	ClpP1P2 protease	T116,T126	C0052605
28317028	2203	2212	regulates	T045	C2755857
28317028	2221	2231	expression	T045	C1171362
28317028	2240	2250	identified	T080	C0205396
28317028	2257	2266	substrate	T167	C3891814
28317028	2277	2286	substrate	T167	C3891814
28317028	2287	2307	recognition sequence	T087	C0002518
28317028	2314	2323	mechanism	T044	C3537153
28317028	2332	2339	ClpP1P2	T116,T126	C0052605
28317028	2340	2350	inhibition	T039	C1524081
28317028	2358	2367	bacterial	T007	C0004611
28317028	2368	2385	growth inhibition	T040	C2249823